- Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin Lispro; Drug: Insulin Aspart
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Technosphere Insulin; Drug: Technosphere Inhalation Powder
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin with MedToneC Inhaler in combination with a basal insulin; Drug: Technosphere Insulin with Gen2C Inhaler in combination with a basal insulin; Drug: Insulin Aspart in combination with a basal insulin
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Intervention: Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2963016; Drug: Lantus; Drug: Oral Antihyperglycemic Medications (OAMs)
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Diabetes; Weight Loss; Physical Function; Cognitive Function
Interventions: Behavioral: Lifestyle intervention; Behavioral: Diabetes Support Education
Sponsors: Wake Forest University; Wake Forest University; Pennington Biomedical Research Center; University of Colorado, Denver; University of Tennessee; University of Pittsburgh
Recruiting - verified September 2011 - Condition: Metabolic Syndrome
Intervention: Dietary Supplement: Blueberry Powder
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center; United States Highbush Blueberry Council; United States Department of Agriculture
Recruiting - verified July 2011 - Condition: Diabetes
Intervention: Device: DRMS
Sponsors: Tulane University School of Medicine; Tulane University School of Medicine; Eli Lilly and Company
Recruiting - verified September 2011 - Condition: Type 2 Diabetes Mellitus
Intervention:
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center
Recruiting - verified July 2011 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Gestational Diabetes Mellitus; Type 2 Diabetes Mellitus; Metabolic Syndrome; Impaired Glucose Tolerance; Impaired Fasting Glucose
Interventions: Drug: Metformin XR only; Drug: Metformin XR plus liraglutide
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Novo Nordisk
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials in Louisiana for Diabetes |
